Collas Crill’s Corporate Finance and Funds team in Guernsey has advised on the launch of Alpha Investment Funds PCC Limited, a registered, closed ended, private investment fund, and the proposed creation of its first cell.
The new fund uses the Guernsey protected cell fund structure, which allows the creation of a number of ‘cells’ or funds within a fund. The fund’s first cell, Alpha Life Sciences Fund (ALS) which is managed by Guernsey licensee Alpha Management Limited, will look to invest in opportunities in the healthcare, medical technology and pharmaceutical industries.
The intention is to create more cells in the future to pursue further opportunities in the cleantech, biotech, environmental and innovation spaces.
Director of Alpha Management Limited Roy Tilleard said: “The input of Gareth Morgan and Paul Wilkes in establishing the Alpha Investment Funds PCC Limited has been invaluable, enabling us to set up an umbrella structure for the creation of diversified fund cells over time. Following the launch of ALS, I look forward to continue working with them as we bring new cells to market”.
Collas Crill Senior Associate Gareth Morgan said: “It has been a genuine pleasure to with Roy and his team on the establishment of this fund structure. They have some exciting and innovative initiatives in the pipeline and we look forward to advising them on the next stages of their growth”.
